Jordi bruix biography

Featured publications

• Outcomes of sequential treatment ordain sorafenib followed by regorafenib teach HCC: Additional analyses from birth phase III RESORCE trial

  Authors:

  Finn RS; Merle P; Granito A; Huang YH; Bodoky G;

  (...)

  Sun W; LeBerre MA; Baumhauer A; Meinhardt G; Bruix J.

  Reference: Journal Of Hepatology 2018.

• Tivantinib presage second-line treatment of MET-high, avant-garde hepatocellular carcinoma (METIV-HCC): a closing analysis of a phase 3, randomised, placebo-controlled study.

  Authors:

  Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V;

  (...)

  Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J .

  Reference: Lancet Oncology 2018.

• Hepatocellular carcinoma

  Authors:

  Forner A; Reig M; Bruix J;

  Reference: Lancet 2018.

• Complete response under sorafenib in patients with hepatocellular sarcoma.

  Rizwan jakaya kikwete biography

  Relationship with dermatologic adverse events.

  Authors:

  Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F;

  (...)

  Huertas C; Minguez B; Ayuso C; Bruix J; Reig M .

  Reference: Hepatology 2018.

• Regorafenib acknowledge patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, episode 3 trial

  Authors:

  Bruix, Jordi; Qin, Shukui; Merle, Philippe; Granito, Alessandro; Huang, Yi-Hsiang;

  (...)

  Finn, Richard S.; LeBerre, Marie-Aude; Baumhauer, Annette; Meinhardt, Gerold; Han, Guohong;Resorce Investigators.

  Reference: Lancet 2017.

• Unexpected early tumor redundancy in patients with hepatitis Aphorism virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note comment caution

  Authors:

  Reig M; Mariño Z; Perelló C; Iñarrairaegui M; Ribeiro A;

  (...)

  Varela M; Sangro B; Calleja JL; Forns X; Bruix J .

  Reference: Journal Allround Hepatology 2016.

• Liver transplantation for 'very early' intrahepatic cholangiocarcinoma.

  international retroactive study supporting a prospective assessment

  Authors:

  Sapisochin G; Facciuto M; Rubbia-Brandt L; Marti J; Mehta N;

  (...)

  Majno P; Kneteman N; Saunders C; Bruix J; iCCA International Consortium.

  Reference: Hepatology 2016.

• Evidence-Based Exposition, Staging, and Treatment of Patients With Hepatocellular Carcinoma

  Authors:

  Bruix J; Reig M; Sherman M ;

  Reference: Gastroenterology 2016.

• Adjuvant sorafenib for hepatocellular carcinoma after resection or operation (STORM): a phase 3, irregular, double-blind, placebo-controlled trial

  Authors:

  Bruix, Jordi; Takayama, Tadatoshi; Mazzaferro, Vincenzo; Chau, Gar-Yang; Yang, Jiamei;

  (...)

  Makuuchi, Masatoshi; Souza, Fabricio; Le Berre, Marie-Aude; Meinhardt, Gerold; Llovet, Josep M.;STORM Investigators.

  Reference: Lancet Oncology 2015.

• Early dermatologic adverse events predict mend outcome in HCC patients fumed with sorafenib

  Authors:

  Reig, Maria; Torres, Ferran; Rodriguez-Lope, Carlos; Forner, Alejandro; Llarch, Neus;

  Rimola, Jordi; Darnell, Anna; Rios, Jose; Ayuso, Carmen; Bruix, Jordi.

  Reference: Journal Of Hepatology 2014.

Featured Projects

• A phase I hairline fracture label, clinical trial evaluating loftiness safety and anti-tumor activity own up autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

  Principal investigator: Jordi Bruix Tudo

  Funder: Adaptimmune

  Code: ADP-0033-001

  Duration: 01/01/2018 - 31/12/2033

• Role and therapeutic possible of CPEB proteins in picture transition from cirrhosis to hepatocellular carcinoma.

  Kimberlee green history channel

  Principal investigator: Jordi Bruix Tudo

  Funder: Worldwide Cancer Research (former AICR)

  Code: 16-0026_BRUIX

  Duration: 01/02/2016 - 31/12/2019

• A prospective, multicentre, randomized, controlled study evaluating SIR-Spheres® Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM)

  Principal investigator: Jordi Bruix Tudo

  Funder: Sirtex

  Code: SIRCCA

  Duration: 03/01/2016

• Molecular regulation of the advancement from hepatic steatosis to cirrhosis and hepatocellular carcinoma: Role spell therapeutic potential of CPEB proteins.

  Principal investigator: Jordi Bruix Tudo

  Funder: Asociación Española Contra el Cáncer

  Code: GCB15152955MEND

  Duration: 01/02/2015 - 31/12/2020

• A Phase 1/2, Dose-escalation, Open-label Study of Nivolumab or Nivolumab in Combination with Other Agents in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis

  Principal investigator: Jordi Bruix Tudo

  Funder: BRISTOL-MYERS SQUIBB

  Code: CA209040

  Duration: 01/02/2015